Health Trials

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

ConditionsAtherosclerosis Cardiovascular DiseaseChronic Kidney Disease
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age50+
SponsorEli Lilly and Company

About this trial

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

Eligibility criteria

Qualifiers

Have established ASCVD and/or CKD

Disqualifiers

Have type 1 diabetes

Have had a major heart condition within 60 days prior to screening

Have New York Heart Association Functional Classification Class IV heart failure

Trial design

Treatments tested in this trial

  • Orforglipron
  • Placebo

Treatment groups

7,140 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Eli Lilly and Company

Lead sponsor

Source ClinicalTrials.gov